VB 1953

Drug Profile

VB 1953

Alternative Names: VB-1953

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vyome Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antibacterials
  • Mechanism of Action Bacterial DNA inhibitors; Bacterial growth inhibitors; Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acne

Most Recent Events

  • 24 Apr 2017 Vyome Biosciences completes enrolment in its proof-of-concept trial for Acne in Central America and Dominican Republic
  • 07 Feb 2017 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Acne released by Vyome Biosciences
  • 07 Feb 2017 Vyome Biosciences plans a phase II trial for Acne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top